EDAP TMS and Avenda Health announced a collaboration agreement for the purpose of offering personalized prostate cancer care, utilizing Avenda’s groundbreaking AI technology, Unfold AI, to launch the world’s first AI-assisted Focal One robotic high-intensity focused ultrasound procedures. Avenda Health’s Unfold AI is a multimodal AI decision support platform cleared by the U.S. Food and Drug Administration that brings “superhuman” abilities to cancer surgeons and oncologists to power the future of cancer care. Unfold AI builds 3D patient-specific cancer maps that reveal invisible tumor extent and enables physicians to avoid leaving cancerous tissue behind while sparing healthy surrounding tissue. By leveraging Unfold AI’s planning with the Focal One robotic HIFU platform, EDAP and Avenda believe that urologists can provide a more tailored, patient-specific HIFU ablation procedure for their prostate cancer patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDAP:
- EDAP and Avenda Health Launch World’s First AI-Assisted Focal One® Robotic HIFU Procedures
- EDAP to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- EDAP TMS Reports Strong Growth and Clinical Advances
- EDAP TMS chairman Marc Oczachowski resigns
- EDAP TMS reports Q2 EPS (EUR 0.16) vs. (EUR 0.13) last year